In vitro platelet inhibition of generic clopidogrel

Background: Clopidogrel is a potent platelet activation and aggregation inhibitor that prevents thrombosis in coronary artery diseases. In comparison to locally produced generic one (Osvix®), original brand of clopidogrel (Plavix) is expensive.Objectives: This study was designed to evaluate the effectiveness and uniformity of Osvix® versus Plavix® in patients with previous percutaneous angioplasty (PCI) by means of platelet aggregation indexes.Patients and Methods: This randomized, double blind clinical study was conducted at Shahid Madani Heart Hospital, Tabriz, Iran, and ۱۲۹ patients with previous PCI were enrolled in two independent treatment groups. All patients participated in this study were on dual antiplatelet therapy at least for ۳۰ days. ASA ۸۰ mg/day and clopidogrel ۷۵ mg/day and a stat dose of ۳۰۰ mg of Clopidogrel before PCI were administered for all patients. To evaluate the anti-platelet activity, blood samples were taken from the patients and platelet aggregation test was performed.Results: The total study population represents a group of ۱۲۹ patients (۹۹ men and ۳۰ women) with mean age of ۵۷.۷ ± ۹.۷ years with stable angina pectoris.The baseline characteristics and laboratory findings of two groups (except MPV)were not different statistically. The mean platelets aggregation at ۳۰th day was ۱۳.۷±۷.۰ in Plavix® group and ۱۴.۸±۵.۸ in Osvix® group (P value=۰.۳۵).Conclusions: This study showed the Iranian brand of Clopidogrel (Osvix®) was not significantly different from the original brand (Plavix) in terms of performance factors in preventing platelet aggregation in patients.

کلیدواژه ها:

Stable angina ، Clopidogrel ، Generic ، Brand ، Platelet aggregation